Collecting blood samples from patients with Huntington's Disease
SAN-09611: Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
This study is collecting blood samples from people with Huntington's Disease to see if a specific test can help with future research on the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5 (estimated) |
| Ages | 25 Years to 65 Years |
| Sex | All |
| Sponsor | Sanguine Biosciences Industry-sponsored |
| Locations | 1 site (Woburn, Massachusetts) |
| Trial ID | NCT05773196 on ClinicalTrials.gov |
What this trial studies
This observational study aims to collect blood samples from individuals diagnosed with Huntington's Disease to validate a specific CAG assay for future research. The study will enroll up to 5 participants who meet the eligibility criteria, including having documented CAG repeat counts. Participants will undergo a single biospecimen collection visit, with the possibility of additional visits if needed. The collected samples will contribute to a biorepository aimed at identifying disease-associated biomarkers and enhancing multi-omics profiling for Huntington's Disease.
Who should consider this trial
Good fit: Ideal candidates are individuals aged 25 to 65 who have been diagnosed with Huntington's Disease and have documented CAG repeat counts between 40-60.
Not a fit: Patients who are pregnant, nursing, or have a history of certain infectious diseases will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and potential new targets for treating Huntington's Disease.
How similar studies have performed: While this approach is focused on biospecimen collection, similar studies have shown promise in identifying biomarkers for neurodegenerative diseases.
Eligibility criteria
Show full inclusion / exclusion criteria
Cohort 1: Huntington's Disease Inclusion: 1. The participant is willing and able to provide written informed consent 2. The participant is willing and able to provide appropriate photo identification 3. Participants aged 25 to 65, inclusive 4. Participants have been diagnosed with Huntington's Disease 5. Patients must have numerical documentation of CAG repeats present in the Medical Record, along with a Huntington's Disease diagnosis. 6. Pre-existing evidence of CAG repeats should be in the range of 40-60 repeats \*Preference (not required for enrollment): Patients to have different CAG repeats from each other but this is not essential.\* Exclusion: 1. Participants who are pregnant or are nursing 2. Participants with a known history of HIV, hepatitis, or other infectious diseases 3. Participants who have taken an investigational product in the last 30 days 4. Participants who have experienced excess blood loss, including blood donation, defined as 250 mL in the last month or 500 mL in the previous two months
Where this trial is running
Woburn, Massachusetts
- Sanguine Biosciences, Inc. — Woburn, Massachusetts, United States (Recruiting)
Study contacts
- Study coordinator: Andrew C Frisina, M.S.
- Email: Afrisina@sanguinebio.com
- Phone: 9782394764
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.